- Axsome Therapeutics (NASDAQ:AXSM) has completed a successful pre-New Drug Application (NDA) meeting with the FDA for AXS-07 for the acute treatment of migraine.
- The purpose of the meeting was to reach an agreement with the Agency on the proposed content and format of the Company’s NDA submission including the clinical and nonclinical requirements.
- The company remains on track to submit the planned NDA in Q4.
Axsome completes pre-NDA meeting for AXS-07
Recommended For You
More Trending News
About AXSM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AXSM | - | - |
Axsome Therapeutics, Inc. |